Akari Therapeutics PLC (AKTX)
0.97
-0.03
(-2.99%)
USD |
NASDAQ |
Dec 20, 16:00
0.95
-0.02
(-2.06%)
After-Hours: 20:00
Akari Therapeutics EPS Diluted (Quarterly): -0.2374 for Sept. 30, 2024
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Earnings per Share Definition
Earnings per share measures the total net income / average shares outstanding during income period. There are a few variations to earnings per share that are listed including "EPS Basic", "EPS Diluted", "Normalized Basic EPS", and "Normalized Diluted EPS". Each of these metrics are dependent on which earnings and shares outstanding metrics are used. Basic and Diluted EPS differ in that diluted shares are the amount of shares outstanding after all convertible securities, options, and warrants are exercised. Normalized EPS allows does not include one-time expenses.
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| DBV Technologies SA | -1.60 |
| Ascendis Pharma AS | -1.892 |
| Cellectis SA | -0.23 |
| Adaptimmune Therapeutics PLC | -0.06 |
| Biodexa Pharmaceuticals PLC | -- |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -2.895M |
| Total Expenses (Quarterly) | 1.852M |
| Enterprise Value | 22.77M |
| Earnings Yield | -283.7% |